COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus)antigen:
Recombinant 2019-nCoV(SARS-CoV-2) P.1 lineage(B.188.8.131.52, Brazilian variant)
Spike RBD Protein(K417T, E484K and N501Y mutant)
Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies.
Validated in functional ELISA, other immunoassays, The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
Products & Information Collection of New variant SARS-COV-2 (2019nCOV) -Brazilian variants: P.1 lineage(B.184.108.40.206)
The world is in midst of the COVID-19 pandemic.The SARS-CoV-2 lineage B.1.1.28 has been evolving in Brazil since February 2020. A new lineage, named P.1 (B.220.127.116.11), contains convergent mutations in the spike (S) protein, including several receptor binding domain (spike RBD) mutations E484K, K417T, and N501Y.
Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the SARS-COV-2 (2019nCOV)-P.1 lineage(B.18.104.22.168, Brazilian variant) of Spike protein & ACE2 competition binding assay, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.